Medcity New’s article discussing the findings from our research on which medtech corporate venture arms are the best partners:
The shift in the stage of investment and where the perceived opportunities in biotech are have had a significant impact. Pharma corporate venture investors have broadened their interest from late stage to earlier stages of investment. Priorities have also shifted from the next blockbuster drug to more personalized treatments.
One of the consistent criticisms of corporate investors is the imperfect balance between strengthening the core business and the investment target.
Read the article in its entirety here.
There is a growing body of case law across multiple jurisdictions (including those that regularly…
As litigation funding becomes more normalized, the disclosure of litigation funding arrangements is a much…
Recently, I met a General Counsel of a mid-cap company who had only just learned…
Mandatory disclosure of litigation funding has arrived in the District of Delaware — at least…
I recently attended the LITFINCON conference in Houston, Texas. This was my first in-person…
n general, the U.S. legal system requires parties to bear their own costs, and does…